1. Tirofiban provides “platelet anesthesia” during cardiopulmonary bypass in baboons 
Yuji Hiramatsu, MDa, Nicolas Gikakis, BSEa, Harry L. Anderson, MDa, Joseph H. Gorman, MDa, Cezary Marcinkiewicz, PhDb, Robert J. Gould, PhDc, Stefan Niewiarowski, MD, PhDb, L.Henry Edmunds, MDa 
The Journal of Thoracic and Cardiovascular Surgery 
Volume 113, Issue 1, Pages (January 1997)
DOI: /S (97)
Copyright © 1997 Mosby, Inc. Terms and Conditions

2. Fig. 1
Heart rate, cardiac output, and mean arterial blood pressure (ABP) before, during, and after CPB for 4 groups. Circles indicate control group (group 1), triangles indicate low-dose group (group 2), squares indicate high-dose group (group 3), and diamonds indicate bolus plus low-dose group (group 4). Values are the mean ± standard error of the mean. Analysis of variance for repeated measures for four groups (statistical significance identified at p < 0.05, for p value or F statistic by analysis of variance). *Significant difference (p < 0.05, unpaired t test with Bonferroni correction) within each group as compared with BASELINE. †Significant difference (p < 0.05, unpaired t test with Bonferroni correction) between each tirofiban group and control.
The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /S (97) )
Copyright © 1997 Mosby, Inc. Terms and Conditions

3. Fig. 1
Heart rate, cardiac output, and mean arterial blood pressure (ABP) before, during, and after CPB for 4 groups. Circles indicate control group (group 1), triangles indicate low-dose group (group 2), squares indicate high-dose group (group 3), and diamonds indicate bolus plus low-dose group (group 4). Values are the mean ± standard error of the mean. Analysis of variance for repeated measures for four groups (statistical significance identified at p < 0.05, for p value or F statistic by analysis of variance). *Significant difference (p < 0.05, unpaired t test with Bonferroni correction) within each group as compared with BASELINE. †Significant difference (p < 0.05, unpaired t test with Bonferroni correction) between each tirofiban group and control.
The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /S (97) )
Copyright © 1997 Mosby, Inc. Terms and Conditions

4. Fig. 2
Hematocrit-corrected platelet counts before, during, and after CPB for four groups. Platelet counts are standardized as a percentage of BASELINE for each time point of the group. Circles indicate control group (group 1), triangles indicate low-dose group (group 2), squares indicate high-dose group (group 3), and diamonds indicate bolus plus low-dose group (group 4). Values are the mean ± standard error of the mean. Analysis of variance for repeated measures for four groups (statistical significance identified at p < 0.05, for p value or F statistic by analysis of variance). *Significant difference (p < 0.05, unpaired t test with Bonferroni correction) within each group as compared with BASELINE. †Significant difference (p < 0.05, unpaired t test with Bonferroni correction) between each tirofiban group and control.
The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /S (97) )
Copyright © 1997 Mosby, Inc. Terms and Conditions

5. Fig. 3
Platelet aggregation to adenosine diphosphate (ADP) before, during, and after CPB for four groups. Data points are standardized as a percentage of BASELINE for each time point of the group. Circles indicate control group (group 1), triangles indicate low-dose group (group 2), squares indicate high-dose group (group 3), and diamonds indicate bolus plus low-dose group (group 4). Values are the mean ± standard error of the mean. Analysis of variance for repeated measures for four groups (statistical significance identified at p < 0.05, for p value or F statistic by analysis of variance). *Significant difference (p < 0.05, unpaired t test with Bonferroni correction) within each group as compared with BASELINE. †Significant difference (p < 0.05, unpaired t test with Bonferroni correction) between each tirofiban group and control.
The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /S (97) )
Copyright © 1997 Mosby, Inc. Terms and Conditions

6. Fig. 4
Hematocrit corrected βTG release before, during, and after CPB for four groups. Circles indicate control group (group 1), triangles indicate low-dose group (group 2), squares indicate high-dose group (group 3), and diamonds indicate bolus plus low-dose group (group 4). Values are the mean ± standard error of the mean. Analysis of variance for repeated measures for four groups (statistical significance identified at p < 0.05, for p value or F statistic by analysis of variance). *Significant difference (p < 0.05, unpaired t test with Bonferroni correction) within each group as compared with BASELINE. †Significant difference (p < 0.05, unpaired t test with Bonferroni correction) between each tirofiban group and control.
The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /S (97) )
Copyright © 1997 Mosby, Inc. Terms and Conditions

7. Fig. 5
Template bleeding times before, during, and after CPB for four groups. Circles indicate control group (group 1), triangles indicate low-dose group (group 2), squares indicate high-dose group (group 3), and diamonds indicate bolus plus low-dose group (group 4). Values are the mean ± standard error of the mean. Analysis of variance for repeated measures for four groups (statistical significance identified at p < 0.05, for p value or F statistic by analysis of variance). *Significant difference (p < 0.05, unpaired t test with Bonferroni correction) within each group as compared with BASELINE. †Significant difference (p < 0.05, unpaired t test with Bonferroni correction) between each tirofiban group and control.
The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /S (97) )
Copyright © 1997 Mosby, Inc. Terms and Conditions